{
  "hash": "c9f9cab43b2b467e0cf958179d3c845a",
  "result": {
    "engine": "knitr",
    "markdown": "---\ntitle: \"Comprehensive Resistome Analysis\"\nsubtitle: \"KPC-31 Carbapenemase-Producing Enterobacterales\"\nauthor: \"Russell Lewis\"\ndate: \"December 26, 2025\"\nformat:\n  html:\n    toc: true\n    toc-depth: 3\n    toc-location: left\n    number-sections: true\n    code-fold: true\n    code-tools: true\n    theme: cosmo\n    embed-resources: true\n    fig-width: 10\n    fig-height: 6\nexecute:\n  warning: false\n  message: false\n  echo: false\n---\n\n\n\n\n\n# Executive Summary {.unnumbered}\n\nThis report presents a comprehensive analysis of 42 bacterial isolates from the KPC-31 resistome project. The dataset includes detailed characterization of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* isolates, with emphasis on:\n\n- **Species and molecular typing** (sequence types, capsular types)\n- **Antimicrobial resistance phenotypes** (MIC values for 26 antibiotics)\n- **Resistance genotypes** (36 resistance genes identified)\n- **Plasmid incompatibility groups** (15 Inc groups detected)\n- **Horizontal gene transfer patterns**\n\n## Key Findings {.unnumbered}\n\n:::{.callout-important}\n## Critical Discovery: Universal blaKPC-31 Carriage\n\n**ALL 42 isolates (100%) carry the blaKPC-31 carbapenemase gene**, indicating this is a KPC-31-specific collection or outbreak. This variant is responsible for the observed carbapenem resistance and variable ceftazidime-avibactam (CAZ-AVI) resistance across isolates.\n:::\n\n- **Dominant species**: *Klebsiella pneumoniae* (78.6%, n=33)\n- **Most prevalent sequence type**: ST307 (50% of typed isolates, n=16)\n- **High-risk clones identified**: ST307, ST512, ST101, ST131, ST147\n- **CAZ-AVI resistance**: 35.7% show high-level resistance (MIC >16 mg/L)\n- **Plasmid diversity**: 15 incompatibility groups, with IncF plasmids spreading across multiple clones\n\n---\n\n# Dataset Overview\n\n## Data Structure\n\n\n::: {.cell}\n::: {.cell-output .cell-output-stdout}\n\n```\nDataset Dimensions:\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stdout}\n\n```\n==================\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stdout}\n\n```\n• Total isolates: 42\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stdout}\n\n```\n• Total variables: 155\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stdout}\n\n```\n• Antibiotics tested (MIC): ~26\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stdout}\n\n```\n• Resistance genes analyzed: 36\n```\n\n\n:::\n\n::: {.cell-output .cell-output-stdout}\n\n```\n• Plasmid Inc groups detected: 15\n```\n\n\n:::\n:::\n\n\n## Data Completeness\n\n\n::: {#tbl-data-completeness .cell tbl-cap='Data completeness for key metadata variables'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover table-condensed\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> Variable </th>\n   <th style=\"text-align:center;\"> Total </th>\n   <th style=\"text-align:center;\"> Complete </th>\n   <th style=\"text-align:center;\"> Missing </th>\n   <th style=\"text-align:center;\"> % Complete </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;\"> ID </td>\n   <td style=\"text-align:center;\"> 42 </td>\n   <td style=\"text-align:center;\"> 42 </td>\n   <td style=\"text-align:center;\"> 0 </td>\n   <td style=\"text-align:center;font-weight: bold;\"> 100.0 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Species </td>\n   <td style=\"text-align:center;\"> 42 </td>\n   <td style=\"text-align:center;\"> 42 </td>\n   <td style=\"text-align:center;\"> 0 </td>\n   <td style=\"text-align:center;font-weight: bold;\"> 100.0 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Clinical Source </td>\n   <td style=\"text-align:center;\"> 42 </td>\n   <td style=\"text-align:center;\"> 32 </td>\n   <td style=\"text-align:center;\"> 10 </td>\n   <td style=\"text-align:center;font-weight: bold;\"> 76.2 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Sequence Type (ST) </td>\n   <td style=\"text-align:center;\"> 42 </td>\n   <td style=\"text-align:center;\"> 32 </td>\n   <td style=\"text-align:center;\"> 10 </td>\n   <td style=\"text-align:center;font-weight: bold;\"> 76.2 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Capsular Type (KL) </td>\n   <td style=\"text-align:center;\"> 42 </td>\n   <td style=\"text-align:center;\"> 10 </td>\n   <td style=\"text-align:center;\"> 32 </td>\n   <td style=\"text-align:center;font-weight: bold;\"> 23.8 </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Wzi Type </td>\n   <td style=\"text-align:center;\"> 42 </td>\n   <td style=\"text-align:center;\"> 9 </td>\n   <td style=\"text-align:center;\"> 33 </td>\n   <td style=\"text-align:center;font-weight: bold;\"> 21.4 </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n---\n\n# Bacterial Characterization\n\n## Species Distribution\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Distribution of bacterial species in the collection](resistome_genotype_phenotype_section_files/figure-html/fig-species-distribution-1.png){#fig-species-distribution width=960}\n:::\n:::\n\n\n::: {.callout-note}\n## Species Composition\n\n- **Klebsiella pneumoniae**: 33/42 isolates (78.6%)\n- **Escherichia coli** variants: 9/42 isolates (21.4%)\n  - *E. coli* TOP10: 5 isolates (lab strain)\n  - *E. coli* DH5-α: 2 isolates (lab strain)\n  - *E. coli*: 2 isolates (clinical)\n:::\n\n## Sequence Types (MLST)\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Distribution of sequence types among typed isolates](resistome_genotype_phenotype_section_files/figure-html/fig-sequence-types-1.png){#fig-sequence-types width=960}\n:::\n:::\n\n\n\n::: {#tbl-sequence-types .cell tbl-cap='Summary of sequence types and their clinical significance'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> ST </th>\n   <th style=\"text-align:center;\"> n </th>\n   <th style=\"text-align:center;\"> Percentage </th>\n   <th style=\"text-align:left;\"> Species </th>\n   <th style=\"text-align:left;\"> Clinical.Significance </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;background-color: rgba(255, 230, 230, 255) !important;\"> ST307 </td>\n   <td style=\"text-align:center;font-weight: bold;background-color: rgba(255, 230, 230, 255) !important;\"> 16 </td>\n   <td style=\"text-align:center;font-weight: bold;background-color: rgba(255, 230, 230, 255) !important;\"> 50.0 </td>\n   <td style=\"text-align:left;font-weight: bold;background-color: rgba(255, 230, 230, 255) !important;\"> K. pneumoniae </td>\n   <td style=\"text-align:left;font-weight: bold;background-color: rgba(255, 230, 230, 255) !important;\"> Global high-risk clone </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ST101 </td>\n   <td style=\"text-align:center;\"> 7 </td>\n   <td style=\"text-align:center;\"> 21.9 </td>\n   <td style=\"text-align:left;\"> K. pneumoniae </td>\n   <td style=\"text-align:left;\"> MDR clone </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ST512 </td>\n   <td style=\"text-align:center;\"> 5 </td>\n   <td style=\"text-align:center;\"> 15.6 </td>\n   <td style=\"text-align:left;\"> K. pneumoniae </td>\n   <td style=\"text-align:left;\"> Emerging high-risk clone </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ST131 </td>\n   <td style=\"text-align:center;\"> 2 </td>\n   <td style=\"text-align:center;\"> 6.3 </td>\n   <td style=\"text-align:left;\"> E. coli </td>\n   <td style=\"text-align:left;\"> Global E. coli pandemic clone </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> ST147 </td>\n   <td style=\"text-align:center;\"> 2 </td>\n   <td style=\"text-align:center;\"> 6.3 </td>\n   <td style=\"text-align:left;\"> K. pneumoniae </td>\n   <td style=\"text-align:left;\"> MDR K. pneumoniae clone </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n## Clinical Sources\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Distribution of clinical specimen types](resistome_genotype_phenotype_section_files/figure-html/fig-clinical-sources-1.png){#fig-clinical-sources width=960}\n:::\n:::\n\n\n## Capsular Types (KL)\n\n\n::: {.cell}\n\n:::\n\n\n::: {.callout-important}\n## Perfect KL-ST Association\n\nEach capsular type is **exclusively associated with one sequence type**, suggesting stable clonal lineages:\n\n- **KL107 ↔ ST512** (n=4)\n- **KL102 ↔ ST307** (n=2)\n- **KL17 ↔ ST101** (n=2)\n- **KL64 ↔ ST147** (n=2)\n\nOnly 23.8% (10/42) of isolates have capsular typing data, but the perfect association is striking.\n:::\n\n---\n\n# Antimicrobial Resistance Phenotypes\n\n## Ceftazidime-Avibactam (CAZ-AVI) Resistance\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Distribution of CAZ-AVI MIC values](resistome_genotype_phenotype_section_files/figure-html/fig-caz-avi-distribution-1.png){#fig-caz-avi-distribution width=960}\n:::\n:::\n\n\n## CAZ-AVI Resistance by Sequence Type\n\n\n::: {.cell}\n::: {.cell-output-display}\n![CAZ-AVI resistance stratified by sequence type](resistome_genotype_phenotype_section_files/figure-html/fig-caz-avi-by-st-1.png){#fig-caz-avi-by-st width=960}\n:::\n:::\n\n\n::: {.callout-warning}\n## ST307 Heterogeneous Resistance\n\nST307 shows a **50/50 split** between intermediate and resistant isolates, suggesting:\n\n- Evolving resistance mechanisms within this clone\n- Potential for further resistance development\n- Need for careful monitoring\n:::\n\n## Multi-Antibiotic Resistance Heatmap\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Median MIC values across antibiotics by sequence type](resistome_genotype_phenotype_section_files/figure-html/fig-resistance-heatmap-1.png){#fig-resistance-heatmap width=960}\n:::\n:::\n\n\n---\n\n# Resistance Genotypes\n\n## blaKPC-31: The Universal Carbapenemase\n\n\n::: {.cell}\n::: {.cell-output-display}\n![blaKPC-31 prevalence across species and sequence types](resistome_genotype_phenotype_section_files/figure-html/fig-kpc31-universal-1.png){#fig-kpc31-universal width=960}\n:::\n:::\n\n\n::: {.callout-important}\n## Universal KPC-31 Carriage\n\n**100% of isolates** (42/42) carry blaKPC-31, including:\n\n- All *K. pneumoniae* isolates\n- All *E. coli* isolates (including lab strains)\n- All sequence types\n- Both clinical and environmental isolates\n\nThis indicates a **KPC-31-specific collection or outbreak**.\n:::\n\n## Resistance Gene Profiles by Clone\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Resistance gene profiles for isolates with capsular typing](resistome_genotype_phenotype_section_files/figure-html/fig-resistance-genes-by-clone-1.png){#fig-resistance-genes-by-clone width=960}\n:::\n:::\n\n\n\n::: {#tbl-gene-summary .cell tbl-cap='Summary of resistance genes by KL/ST combination'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> Clone </th>\n   <th style=\"text-align:center;\"> Total.Genes </th>\n   <th style=\"text-align:left;\"> Beta.lactamases </th>\n   <th style=\"text-align:left;\"> Key.Features </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL64 (ST147) </td>\n   <td style=\"text-align:center;\"> 15 </td>\n   <td style=\"text-align:left;\"> KPC-31, CTX-M-15, TEM-1B, SHV-11, OXA-1 </td>\n   <td style=\"text-align:left;\"> Most genes; fosfomycin resistance </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL102 (ST307) </td>\n   <td style=\"text-align:center;\"> 13 </td>\n   <td style=\"text-align:left;\"> KPC-31, CTX-M-15, TEM-1B, SHV-28, OXA-1 </td>\n   <td style=\"text-align:left;\"> qnrB1 quinolone resistance </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL107 (ST512) </td>\n   <td style=\"text-align:center;\"> 12 </td>\n   <td style=\"text-align:left;\"> KPC-31, TEM-1A, SHV-158 </td>\n   <td style=\"text-align:left;\"> IncX3 plasmid-associated </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL17 (ST101) </td>\n   <td style=\"text-align:center;\"> 5 </td>\n   <td style=\"text-align:left;\"> KPC-31, SHV-1 </td>\n   <td style=\"text-align:left;\"> armA (pan-AMG resistance) </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n::: {.callout-note}\n## Notable Findings\n\n- **KL64 (ST147)**: Highest gene count (15), includes fosA (fosfomycin resistance)\n- **KL17 (ST101)**: Lowest gene count (5), but includes armA conferring pan-aminoglycoside resistance\n- **KL102 (ST307)**: Carries qnrB1 providing quinolone resistance\n- **KL107 (ST512)**: Associated with IncX3 plasmid\n:::\n\n---\n\n# Capsular Type-Resistance Associations\n\n## KL-ST Perfect Association\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Perfect 1:1 association between capsular types and sequence types](resistome_genotype_phenotype_section_files/figure-html/fig-kl-st-association-1.png){#fig-kl-st-association width=960}\n:::\n:::\n\n\n## CAZ-AVI Resistance by Capsular Type\n\n\n::: {.cell}\n::: {.cell-output-display}\n![CAZ-AVI resistance profiles differ dramatically by capsular type](resistome_genotype_phenotype_section_files/figure-html/fig-caz-avi-by-kl-1.png){#fig-caz-avi-by-kl width=960}\n:::\n:::\n\n\n\n::: {#tbl-kl-resistance-summary .cell tbl-cap='CAZ-AVI resistance profiles by capsular type'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> KL.Type </th>\n   <th style=\"text-align:left;\"> ST </th>\n   <th style=\"text-align:center;\"> n </th>\n   <th style=\"text-align:center;\"> Median.MIC </th>\n   <th style=\"text-align:left;\"> Resistance.Status </th>\n   <th style=\"text-align:left;\"> Clinical.Concern </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> KL64 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> ST147 </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 2 </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 256 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> 100% Resistant </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Very High </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> KL17 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> ST101 </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 2 </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 130 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> 100% Resistant </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Very High </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> KL107 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> ST512 </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 4 </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 48 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> 100% Resistant </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> High </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> KL102 </td>\n   <td style=\"text-align:left;\"> ST307 </td>\n   <td style=\"text-align:center;\"> 2 </td>\n   <td style=\"text-align:center;\"> 12 </td>\n   <td style=\"text-align:left;\"> 100% Intermediate </td>\n   <td style=\"text-align:left;\"> Moderate </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n---\n\n# Plasmid Incompatibility Groups\n\n## Inc Group Distribution\n\n\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Prevalence of major incompatibility groups](resistome_genotype_phenotype_section_files/figure-html/fig-inc-prevalence-1.png){#fig-inc-prevalence width=960}\n:::\n:::\n\n\n## Inc Groups by Clone\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Incompatibility group distribution by KL/ST combination](resistome_genotype_phenotype_section_files/figure-html/fig-inc-by-clone-1.png){#fig-inc-by-clone width=960}\n:::\n:::\n\n\n::: {.callout-important}\n## Clone-Specific Plasmid Profiles\n\n- **KL107 (ST512)**: IncX3 (100%) - fixed, likely carries blaKPC-31\n- **KL17 (ST101)**: IncR (50%) - may carry armA gene\n- **KL64 (ST147)**: IncF family (50%) - high HGT potential\n- **KL102 (ST307)**: NO Inc groups detected - chromosomal integration?\n:::\n\n## Horizontal Gene Transfer Evidence\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Plasmid diversity indicates horizontal gene transfer potential](resistome_genotype_phenotype_section_files/figure-html/fig-hgt-evidence-1.png){#fig-hgt-evidence width=960}\n:::\n:::\n\n\n\n::: {#tbl-hgt-summary .cell tbl-cap='Evidence for horizontal gene transfer by Inc group'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> Inc.Group </th>\n   <th style=\"text-align:left;\"> Distribution </th>\n   <th style=\"text-align:center;\"> HGT.Evidence </th>\n   <th style=\"text-align:left;\"> Significance </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> IncFIB(K) / IncFII(K) </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> 4 different STs </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> ★★★★★ High </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Active dissemination within K. pneumoniae </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> IncX3 </td>\n   <td style=\"text-align:left;\"> ST512 only </td>\n   <td style=\"text-align:center;\"> ★☆☆☆☆ None </td>\n   <td style=\"text-align:left;\"> Clone-specific, stable, not spreading </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> IncR </td>\n   <td style=\"text-align:left;\"> Primarily ST101 </td>\n   <td style=\"text-align:center;\"> ★★☆☆☆ Limited </td>\n   <td style=\"text-align:left;\"> May carry armA, limited to one clone </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> IncN </td>\n   <td style=\"text-align:left;\"> Rare, isolated </td>\n   <td style=\"text-align:center;\"> ★★★☆☆ Moderate </td>\n   <td style=\"text-align:left;\"> Recent acquisition, broad host range potential </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n---\n\n# Integrated Analysis\n\n## Relationships Between Plasmids, Genes, and Resistance\n\n\n::: {.cell}\n::: {.cell-output-display}\n![Integrated view of plasmid complexity, gene burden, and resistance levels](resistome_genotype_phenotype_section_files/figure-html/fig-integrated-analysis-1.png){#fig-integrated-analysis width=960}\n:::\n:::\n\n\n::: {.callout-note}\n## Key Paradoxes\n\n1. **KL102 (ST307)**: Zero Inc groups but 13 resistance genes → Chromosomal integration?\n2. **KL17 (ST101)**: High plasmid complexity (2.3) but only 5 genes → Quality over quantity (armA effect)\n3. **KL64 (ST147)**: Most genes (15) and highest MIC (256) → Synergistic effects\n:::\n\n## Summary Table: Clone Characteristics\n\n\n::: {#tbl-clone-summary .cell tbl-cap='Comprehensive summary of clone characteristics'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover\" style=\"font-size: 11px; margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> Clone </th>\n   <th style=\"text-align:center;\"> n </th>\n   <th style=\"text-align:left;\"> CAZ.AVI </th>\n   <th style=\"text-align:center;\"> Resistance.Genes </th>\n   <th style=\"text-align:left;\"> Key.Genes </th>\n   <th style=\"text-align:left;\"> Dominant.Plasmid </th>\n   <th style=\"text-align:center;\"> HGT.Risk </th>\n   <th style=\"text-align:left;\"> Clinical.Priority </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL107 (ST512) </td>\n   <td style=\"text-align:center;\"> 4 </td>\n   <td style=\"text-align:left;\"> Resistant (48) </td>\n   <td style=\"text-align:center;\"> 12 </td>\n   <td style=\"text-align:left;\"> blaKPC-31, blaTEM-1A </td>\n   <td style=\"text-align:left;\"> IncX3 (100%) </td>\n   <td style=\"text-align:center;\"> Low </td>\n   <td style=\"text-align:left;\"> High </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;background-color: rgba(255, 235, 238, 255) !important;\"> KL17 (ST101) </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 2 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Resistant (130) </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 5 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> blaKPC-31, armA </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> IncR (50%) </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> Low </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Very High </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;background-color: rgba(255, 235, 238, 255) !important;\"> KL64 (ST147) </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 2 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Resistant (256) </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> 15 </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> blaKPC-31, CTX-M-15, fosA </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> IncF (50%) </td>\n   <td style=\"text-align:center;background-color: rgba(255, 235, 238, 255) !important;\"> High </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Very High </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL102 (ST307) </td>\n   <td style=\"text-align:center;\"> 2 </td>\n   <td style=\"text-align:left;\"> Intermediate (12) </td>\n   <td style=\"text-align:center;\"> 13 </td>\n   <td style=\"text-align:left;\"> blaKPC-31, CTX-M-15, qnrB1 </td>\n   <td style=\"text-align:left;\"> None detected </td>\n   <td style=\"text-align:center;\"> Unknown </td>\n   <td style=\"text-align:left;\"> Monitor </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n---\n\n# Clinical Implications\n\n## Treatment Challenges\n\n::: {.callout-warning}\n## Extremely Limited Treatment Options\n\nAll isolates carry blaKPC-31, resulting in:\n\n- ✗ **Carbapenems**: Compromised by carbapenemase\n- ⚠️ **CAZ-AVI**: Variable resistance (35.7% high-level)\n- ⚠️ **Aminoglycosides**: Compromised (especially ST101 with armA)\n- ⚠️ **Quinolones**: Resistance common (gyrA, ParC, qnrB1)\n:::\n\n### Potential Treatment Strategies\n\n\n::: {#tbl-treatment-options .cell tbl-cap='Potential treatment options by clone type'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> Clone </th>\n   <th style=\"text-align:left;\"> First.Line </th>\n   <th style=\"text-align:left;\"> Second.Line </th>\n   <th style=\"text-align:left;\"> Last.Resort </th>\n   <th style=\"text-align:left;\"> Notes </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL107 (ST512) </td>\n   <td style=\"text-align:left;\"> Cefiderocol </td>\n   <td style=\"text-align:left;\"> Carbapenem + AVI </td>\n   <td style=\"text-align:left;\"> Colistin </td>\n   <td style=\"text-align:left;\"> IncX3-stable resistance </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL17 (ST101) </td>\n   <td style=\"text-align:left;\"> Cefiderocol </td>\n   <td style=\"text-align:left;\"> Plazomicin (not armA) </td>\n   <td style=\"text-align:left;\"> Colistin </td>\n   <td style=\"text-align:left;\"> armA limits aminoglycosides </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL64 (ST147) </td>\n   <td style=\"text-align:left;\"> Combination therapy </td>\n   <td style=\"text-align:left;\"> Carbapenem + fosfomycin </td>\n   <td style=\"text-align:left;\"> Colistin </td>\n   <td style=\"text-align:left;\"> High gene burden, test all options </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;font-weight: bold;\"> KL102 (ST307) </td>\n   <td style=\"text-align:left;\"> Carbapenems </td>\n   <td style=\"text-align:left;\"> CAZ-AVI </td>\n   <td style=\"text-align:left;\"> Colistin </td>\n   <td style=\"text-align:left;\"> Best prognosis of 4 clones </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n## Infection Control Priorities\n\n### High-Risk Clones for Isolation\n\n1. **ST512 (KL107)**: IncX3 plasmid stable but high resistance\n2. **ST101 (KL17)**: armA-mediated pan-aminoglycoside resistance\n3. **ST147 (KL64)**: IncF plasmids with high HGT potential\n\n### Surveillance Recommendations\n\n\n::: {.cell}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover\" style=\"margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> Priority </th>\n   <th style=\"text-align:left;\"> Target </th>\n   <th style=\"text-align:left;\"> Rationale </th>\n  </tr>\n </thead>\n<tbody>\n  <tr>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Critical </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> IncF plasmid spread </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Spreading across 4 STs, HGT evidence </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Critical </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> blaKPC-31 variants </td>\n   <td style=\"text-align:left;background-color: rgba(255, 235, 238, 255) !important;\"> Monitor for evolution (KPC-32, KPC-33, etc.) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;background-color: rgba(255, 243, 224, 255) !important;\"> High </td>\n   <td style=\"text-align:left;background-color: rgba(255, 243, 224, 255) !important;\"> ST307 mechanism </td>\n   <td style=\"text-align:left;background-color: rgba(255, 243, 224, 255) !important;\"> No Inc groups detected - chromosomal integration? </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;background-color: rgba(255, 243, 224, 255) !important;\"> High </td>\n   <td style=\"text-align:left;background-color: rgba(255, 243, 224, 255) !important;\"> Capsular typing </td>\n   <td style=\"text-align:left;background-color: rgba(255, 243, 224, 255) !important;\"> Strong predictor of resistance phenotype </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;\"> Moderate </td>\n   <td style=\"text-align:left;\"> CAZ-AVI MICs </td>\n   <td style=\"text-align:left;\"> Early detection of resistance evolution </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n---\n\n# Conclusions\n\n## Key Findings Summary\n\n1. **Universal blaKPC-31 carriage** (100%, 42/42) defines this collection\n2. **ST307 is dominant** (50% of typed isolates) but shows heterogeneous resistance\n3. **Perfect KL-ST associations** indicate stable clonal lineages\n4. **IncF plasmids are disseminating** across multiple K. pneumoniae clones\n5. **Clone-specific resistance mechanisms**:\n   - ST512: IncX3-based (stable, not spreading)\n   - ST101: IncR-based (armA-mediated pan-AMG resistance)\n   - ST147: IncF-based (high HGT risk)\n   - ST307: Unknown mechanism (requires investigation)\n\n## Critical Questions for Further Investigation\n\n::: {.callout-tip}\n## Recommended Next Steps\n\n1. **Whole plasmid sequencing**: Map complete genetic context of resistance genes\n2. **ST307 mechanism**: Investigate chromosomal vs cryptic plasmid integration\n3. **IncX3 plasmid characterization**: Complete sequence of ST512 blaKPC-31-bearing plasmid\n4. **Temporal analysis**: If collection dates available, track resistance evolution\n5. **Epidemiological links**: Investigate patient/ward connections for transmission chains\n6. **Functional studies**: Test plasmid transferability and fitness costs\n:::\n\n## Public Health Implications\n\n::: {.callout-important}\n## Outbreak Potential\n\nThis collection represents either:\n\n- A **KPC-31-specific outbreak** with multiple introductions\n- A **surveillance collection** of endemic KPC-31 strains\n- **Clonal expansion** of resistant lineages with horizontal gene transfer\n\nThe presence of **high-risk global clones** (ST307, ST512, ST101, ST131, ST147) combined with **active plasmid dissemination** (IncF family) represents a significant public health concern requiring immediate infection control measures.\n:::\n\n---\n\n# Methods\n\n## Data Source\n\n- Dataset: Progetto 1 (KPC-31) versione 2.xlsx\n- 42 bacterial isolates\n- 155 variables including:\n  - Bacterial identification (species, MLST, capsular typing)\n  - Antimicrobial susceptibility testing (MIC for ~26 antibiotics)\n  - Resistance gene detection (36 genes)\n  - Plasmid replicon typing (15 incompatibility groups)\n\n## Analytical Approach\n\nAll analyses were performed using R version 4.5.1 with the following packages:\n\n- `tidyverse` for data manipulation and visualization\n- `readxl` for Excel file import\n- `ggplot2` for graphics\n- `knitr` and `kableExtra` for tables\n\n### Resistance Categorization\n\n- **CAZ-AVI Susceptible**: MIC ≤8 mg/L\n- **CAZ-AVI Intermediate**: MIC 9-16 mg/L\n- **CAZ-AVI Resistant**: MIC >16 mg/L\n\n### Statistical Notes\n\n- Percentages calculated on non-missing values\n- Median MIC used for heatmaps to reduce outlier effects\n- Log2 transformation applied for MIC visualization\n\n---\n\n# Appendix\n\n## Complete Resistance Gene List\n\n\n::: {#tbl-complete-gene-list .cell tbl-cap='Complete list of resistance genes detected in the dataset'}\n::: {.cell-output-display}\n`````{=html}\n<table class=\"table table-striped table-hover\" style=\"font-size: 10px; margin-left: auto; margin-right: auto;\">\n <thead>\n  <tr>\n   <th style=\"text-align:left;\"> Category </th>\n   <th style=\"text-align:left;\"> Gene </th>\n   <th style=\"text-align:left;\"> Mechanism </th>\n  </tr>\n </thead>\n<tbody>\n  <tr grouplength=\"11\"><td colspan=\"3\" style=\"border-bottom: 1px solid;\"><strong>Beta-lactamases</strong></td></tr>\n<tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> BlaKPC-31 </td>\n   <td style=\"text-align:left;\"> Carbapenemase (KPC) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> BlaCTXM-15 </td>\n   <td style=\"text-align:left;\"> ESBL (CTX-M) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> blaTEM-1A </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (TEM) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> blaTEM-1B </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (TEM) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> blaSHV-1 </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (SHV) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> blaSHV-11 </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (SHV) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> blaSHV-28 </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (SHV) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> BlaSHV-106 </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (SHV) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> BlaSHV-158 </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (SHV) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> blaOXA-1 </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (OXA) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Beta-lactamases </td>\n   <td style=\"text-align:left;\"> bla OXA-9 </td>\n   <td style=\"text-align:left;\"> Beta-lactamase (OXA) </td>\n  </tr>\n  <tr grouplength=\"8\"><td colspan=\"3\" style=\"border-bottom: 1px solid;\"><strong>Aminoglycosides</strong></td></tr>\n<tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Aminoglycosides </td>\n   <td style=\"text-align:left;\"> aadA </td>\n   <td style=\"text-align:left;\"> Aminoglycoside acetyltransferase </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Aminoglycosides </td>\n   <td style=\"text-align:left;\"> aaaA2 </td>\n   <td style=\"text-align:left;\"> Aminoglycoside resistance </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Aminoglycosides </td>\n   <td style=\"text-align:left;\"> aac(6′)-Ib' </td>\n   <td style=\"text-align:left;\"> Aminoglycoside acetyltransferase </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Aminoglycosides </td>\n   <td style=\"text-align:left;\"> aac(6´)-Ib-cr </td>\n   <td style=\"text-align:left;\"> AMG + FQ resistance </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Aminoglycosides </td>\n   <td style=\"text-align:left;\"> ant(2′')-Ia </td>\n   <td style=\"text-align:left;\"> Aminoglycoside nucleotidyltransferase </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Aminoglycosides </td>\n   <td style=\"text-align:left;\"> aac(3)-IIa </td>\n   <td style=\"text-align:left;\"> Aminoglycoside acetyltransferase </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Aminoglycosides </td>\n   <td style=\"text-align:left;\"> armA </td>\n   <td style=\"text-align:left;\"> 16S rRNA methylase (pan-AMG) </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Aminoglycosides </td>\n   <td style=\"text-align:left;\"> aph(3')-Ia </td>\n   <td style=\"text-align:left;\"> Aminoglycoside phosphotransferase </td>\n  </tr>\n  <tr grouplength=\"3\"><td colspan=\"3\" style=\"border-bottom: 1px solid;\"><strong>Quinolones</strong></td></tr>\n<tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Quinolones </td>\n   <td style=\"text-align:left;\"> ParC </td>\n   <td style=\"text-align:left;\"> DNA gyrase mutation </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Quinolones </td>\n   <td style=\"text-align:left;\"> gyrA </td>\n   <td style=\"text-align:left;\"> DNA gyrase mutation </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Quinolones </td>\n   <td style=\"text-align:left;\"> qnrB1 </td>\n   <td style=\"text-align:left;\"> Quinolone resistance </td>\n  </tr>\n  <tr grouplength=\"3\"><td colspan=\"3\" style=\"border-bottom: 1px solid;\"><strong>Other Mechanisms</strong></td></tr>\n<tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Other </td>\n   <td style=\"text-align:left;\"> Sul1 </td>\n   <td style=\"text-align:left;\"> Sulfonamide resistance </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Other </td>\n   <td style=\"text-align:left;\"> Sul2 </td>\n   <td style=\"text-align:left;\"> Sulfonamide resistance </td>\n  </tr>\n  <tr>\n   <td style=\"text-align:left;padding-left: 2em;\" indentlevel=\"1\"> Other </td>\n   <td style=\"text-align:left;\"> fosA </td>\n   <td style=\"text-align:left;\"> Fosfomycin resistance </td>\n  </tr>\n</tbody>\n</table>\n\n`````\n:::\n:::\n\n\n## Abbreviations\n\n- **AMG**: Aminoglycoside\n- **CAZ-AVI**: Ceftazidime-avibactam\n- **ESBL**: Extended-spectrum beta-lactamase\n- **HGT**: Horizontal gene transfer\n- **Inc**: Incompatibility\n- **KL**: Capsular type (K locus)\n- **MDR**: Multi-drug resistant\n- **MIC**: Minimum inhibitory concentration\n- **MLST**: Multi-locus sequence typing\n- **ST**: Sequence type\n\n---\n\n## Session Information\n\n\n::: {.cell}\n\n```{.r .cell-code}\nsessionInfo()\n```\n\n::: {.cell-output .cell-output-stdout}\n\n```\nR version 4.5.1 (2025-06-13)\nPlatform: aarch64-apple-darwin20\nRunning under: macOS Tahoe 26.3\n\nMatrix products: default\nBLAS:   /Library/Frameworks/R.framework/Versions/4.5-arm64/Resources/lib/libRblas.0.dylib \nLAPACK: /Library/Frameworks/R.framework/Versions/4.5-arm64/Resources/lib/libRlapack.dylib;  LAPACK version 3.12.1\n\nlocale:\n[1] C.UTF-8/C.UTF-8/C.UTF-8/C/C.UTF-8/C.UTF-8\n\ntime zone: Europe/Rome\ntzcode source: internal\n\nattached base packages:\n[1] stats     graphics  grDevices utils     datasets  methods   base     \n\nother attached packages:\n [1] kableExtra_1.4.0 knitr_1.50       readxl_1.4.5     lubridate_1.9.4 \n [5] forcats_1.0.1    stringr_1.6.0    dplyr_1.1.4      purrr_1.2.0     \n [9] readr_2.1.6      tidyr_1.3.1      tibble_3.3.0     ggplot2_4.0.1   \n[13] tidyverse_2.0.0 \n\nloaded via a namespace (and not attached):\n [1] gtable_0.3.6       jsonlite_2.0.0     compiler_4.5.1     tidyselect_1.2.1  \n [5] xml2_1.5.1         textshaping_1.0.4  systemfonts_1.3.1  scales_1.4.0      \n [9] yaml_2.3.12        fastmap_1.2.0      R6_2.6.1           labeling_0.4.3    \n[13] generics_0.1.4     htmlwidgets_1.6.4  svglite_2.2.2      pillar_1.11.1     \n[17] RColorBrewer_1.1-3 tzdb_0.5.0         rlang_1.1.6        stringi_1.8.7     \n[21] xfun_0.55          S7_0.2.1           viridisLite_0.4.2  timechange_0.3.0  \n[25] cli_3.6.5          withr_3.0.2        magrittr_2.0.4     digest_0.6.39     \n[29] grid_4.5.1         rstudioapi_0.17.1  hms_1.1.4          lifecycle_1.0.4   \n[33] vctrs_0.6.5        evaluate_1.0.5     glue_1.8.0         cellranger_1.1.0  \n[37] farver_2.1.2       rmarkdown_2.30     tools_4.5.1        pkgconfig_2.0.3   \n[41] htmltools_0.5.9   \n```\n\n\n:::\n:::\n\n\n---\n\n**Report generated on:** December 28, 2025\n\n**Analysis platform:** Positron 2025.12.2 with R 4.5.1",
    "supporting": [
      "resistome_genotype_phenotype_section_files"
    ],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {
      "include-in-header": [
        "<script src=\"site_libs/kePrint-0.0.1/kePrint.js\"></script>\n<link href=\"site_libs/lightable-0.0.1/lightable.css\" rel=\"stylesheet\" />\n"
      ]
    },
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}